Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/173 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME14677191
PMID: | 14677191
LR: | 20061115
CED: | 20031216
DCO: | 20040105
Autoren: | El Hajjaji H; Marcelis A; Devogelaer JP; Manicourt DH
Titel: | Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage.
Quelle: | The Journal of rheumatology; VOL: 30 (11); p. 2444-51 /200311/
PM: | Print
SU: | IM
Sprache: | English
CY: | Canada
JID: | 7501984
ISSN: | 0315-162X
CO: | JRHUA9
Institution: | ICP Christian de Duve Institute of Cellular Pathology and the Department of Rheumatology, Saint-Luc University Hospital, Catholic University of Louvain, Avenue Mounier, 1200 Brussels, Belgium.
DT: | In Vitro; Journal Article; Research Support, Non-U.S. Gov't
Schlagwörter
CT: | AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/administration & dosage; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*pharmacology; CARTILAGE, ARTICULAR/*drug effects; CARTILAGE, ARTICULAR/metabolism; DICLOFENAC/pharmacology; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYALURONIC ACID/biosynthesis; HYALURONIC ACID/*metabolism; MALE; MIDDLE AGED; OSTEOARTHRITIS/*metabolism; PROTEOGLYCANS/biosynthesis; PROTEOGLYCANS/*metabolism; PYRAZOLES; SULFONAMIDES/administration & dosage; SULFONAMIDES/*pharmacology
CTG: | ALTE MENSCHEN; ANTIPHLOGISTIKA, NICHTSTEROIDALE/Verabreichung & Dosierung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*Pharmakologie; KNORPEL, GELENK-/*Arzneimittelwirkungen; KNORPEL, GELENK-/Stoffwechsel; DICLOFENAC/Pharmakologie; DOSIS-WIRKUNGSBEZIEHUNG, ARZNEIMITTEL-; WEIBLICH; MENSCH; HYALURONSÄURE/Biosynthese; HYALURONSÄURE/*Stoffwechsel; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/*Stoffwechsel; PROTEOGLYCANE/Biosynthese; PROTEOGLYCANE/*Stoffwechsel; PYRAZOLE; SULFONAMIDE/Verabreichung & Dosierung; SULFONAMIDE/*Pharmakologie
TE: | Anti-Inflammatory Agents, Non-Steroidal; Proteoglycans; Pyrazoles; Sulfonamides; Diclofenac/15307-86-5; celecoxib/169590-42-5; Hyaluronic Acid/9004-61-9
CR: | 15307-86-5; 169590-42-5; 9004-61-9
AB: | OBJECTIVE: To assess the effects of celecoxib, a cyclooxygenase (COX-2) selective inhibitor, on the metabolism of hyaluronan (HA) and proteoglycans (PG) in human cartilage explants with midrange severity of osteoarthritis (OA). Results were compared with those of diclofenac, a non-selective COX inhibitor. METHODS: Cartilage specimens (OA grade 4-8 on Mankin's scale) were pulsed with 3H -glucosamine and chased in the absence or presence of 1-10 micro g/ml of celecoxib or diclofenac. After papain digestion, the labeled chondroitin sulfate and HA molecules were purified by anion-exchange chromatography. RESULTS: Diclofenac did not affect the metabolic balance of PG and HA whereas, in a relatively dose-dependent manner, celecoxib increased the synthesis of HA and PG; celecoxib also reduced the net loss of labeled HA and PG molecules from cartilage explants. CONCLUSION: In short term in vitro cultures, celecoxib has a favorable effect on the overall metabolism of PG and HA. It is therefore unlikely that this drug would have a detrimental effect on articular cartilage during longterm administration. Further, celecoxib might help counteract the depletion of HA seen in OA cartilage.

» Volltext »
» Fenster schließen »